Epothilones in breast cancer: Current status and future directions Journal Article
| Authors: | Atzori, F.; Fornier, M. |
| Article Title: | Epothilones in breast cancer: Current status and future directions |
| Abstract: | Taxanes have become fundamental in the treatment of early and advanced breast cancer. However, tumors vary in their sensitivity to these agents; resistance can be acquired or de novo resistance can occur. Epothilones and associated analogs are novel microtubule-stabilizing agents that induce apoptosis and promote cell death. There is now a growing body of clinical data describing the efficacy of epothilones in breast cancer patients who have progressed on taxanes and anthracyclines. This culminated with US FDA approval in October 2007 of ixabepilone (Ixempra™, Brystol Myers Squibb, NJ, USA) either as single agent or in combination with capecitabine for the treatment of breast cancer, which has progressed after prior therapies. The results of ongoing and future randomized clinical trials will further define how epothilones, in particular ixabepilone, will be integrated into the management of early and metastatic breast cancer. In parallel, the search for biomarkers predictive of sensitivity to epothilones continues in an attempt to tailor these therapies to patients with greater accuracy. © 2008 Expert Reviews Ltd. |
| Keywords: | unclassified drug; clinical trial; drug tolerability; fatigue; neutropenia; review; bevacizumab; doxorubicin; fluorouracil; cancer growth; diarrhea; drug dose reduction; drug efficacy; drug withdrawal; monotherapy; recommended drug dose; solid tumor; unspecified side effect; clinical trials as topic; united states; united states food and drug administration; capecitabine; gemcitabine; paclitaxel; adjuvant therapy; disease free survival; pancreas cancer; neurotoxicity; antineoplastic agent; carboplatin; melanoma; infection; multiple cycle treatment; ovary cancer; sensory neuropathy; breast cancer; anemia; bone marrow suppression; blood toxicity; gastrointestinal symptom; leukopenia; lung non small cell cancer; mucosa inflammation; nausea; neuropathy; stomatitis; thrombocytopenia; myalgia; peripheral neuropathy; drug dosage form comparison; combination chemotherapy; cyclophosphamide; antineoplastic activity; continuous infusion; drug structure; food and drug administration; breast neoplasms; cetuximab; cancer resistance; docetaxel; abdominal pain; arthralgia; asthenia; dizziness; drug dose escalation; drug hypersensitivity; febrile neutropenia; loading drug dose; chemotherapy induced emesis; cancer regression; drug mechanism; head and neck cancer; dosage schedule comparison; colon cancer; breast tumor; breast carcinoma; sepsis; epirubicin; platinum; pharmacogenetics; maximum tolerated dose; taxane derivative; anthracycline derivative; corticosteroid; trastuzumab; drug dose increase; navelbine; testis cancer; hand foot syndrome; alopecia; ataxia; everolimus; lapatinib; ixabepilone; epothilones; epothilone b; epothilone d; epothilone derivative; tubulin modulator; tubulin modulators; antihistaminic agent; motor neuropathy; vulva cancer; demyelination; musculoskeletal pain; pharyngitis; nerve fiber degeneration; bms-247550; biomarker development; bms-310705; kos-862; patupilone; ambraxane; b 63651; bms 310705; ixempra; kos 1584 |
| Journal Title: | Expert Review of Anticancer Therapy |
| Volume: | 8 |
| Issue: | 8 |
| ISSN: | 1473-7140 |
| Publisher: | Taylor & Francis Group |
| Date Published: | 2008-08-01 |
| Start Page: | 1299 |
| End Page: | 1311 |
| Language: | English |
| DOI: | 10.1586/14737140.8.8.1299 |
| PUBMED: | 18699766 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 6" - "Export Date: 17 November 2011" - "CODEN: ERATB" - "Source: Scopus" |
